SGN-CD33A: A Novel CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Preclinical Antitumor Activity Against Multi-Drug Resistant Human AML

被引：5
|
作者：
Sutherland, May S. K. [1 ]
Walter, Roland B. [2 ]
Jeffrey, Scott C. [1 ]
Burke, Patrick J. [1 ]
Yu, Changpu [1 ]
Harrington, Kimberly H. [2 ]
Stone, Ivan [1 ]
Ryan, Maureen C. [1 ]
Sussman, Django [1 ]
Zeng, Weiping [1 ]
Benjamin, Dennis R. [1 ]
Bernstein, Irwin D. [2 ]
Senter, Peter D. [1 ]
Drachman, Jonathan G. [1 ]
McEarchern, Julie A. [1 ]
机构：
[1] Seattle Genet Inc, Res & Translat Med, Bothell, WA USA
[2] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.3589.3589
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3589
引用
收藏
页数：2
相关论文
共 45 条
  • [1] SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
    Sutherland, May S. Kung
    Walter, Roland B.
    Jeffrey, Scott C.
    Burke, Patrick J.
    Yu, Changpu
    Kostner, Heather
    Stone, Ivan
    Ryan, Maureen C.
    Sussman, Django
    Lyon, Robert P.
    Zeng, Weiping
    Harrington, Kimberly H.
    Klussman, Kerry
    Westendorf, Lori
    Meyer, David
    Bernstein, Irwin D.
    Senter, Peter D.
    Benjamin, Dennis R.
    Drachman, Jonathan G.
    McEarchern, Julie A.
    BLOOD, 2013, 122 (08) : 1455 - 1463
  • [2] SGN-CD33A: Preclinical and phase 1 interim clinical trial results of a CD33-directed PBD dimer antibody-drug conjugate for the treatment of acute myeloid leukemia (AML)
    Kennedy, Dana A.
    Alley, Stephen C.
    Zhao, Baiteng
    Feldman, Eric J.
    O'Meara, Megan
    Sutherland, May
    CANCER RESEARCH, 2015, 75
  • [3] SGN-CD33A in Combination with Cytarabine or Hypomethylating Agents Demonstrates Enhanced Anti-Leukemic Activity in Preclinical Models of AML
    Sutherland, May S. K.
    Yu, Changpu
    Anderson, Martha
    Emmerton, Kim
    Zeng, Weiping
    O'Meara, Megan M.
    Kennedy, Dana A.
    Ryan, Maureen C.
    Benjamin, Dennis R.
    BLOOD, 2014, 124 (21)
  • [4] SGN-CD123A, a Pyrrolobenzodiazepine Dimer Linked Anti-CD123 Antibody Drug Conjugate, Demonstrates Effective Anti-Leukemic Activity in Multiple Preclinical Models of AML
    Sutherland, May S. K.
    Yu, Changpu
    Walter, Roland B.
    Westendorf, Lori
    Valliere-Douglass, John
    Pan, Lucy
    Sussman, Django
    Anderson, Martha
    Zeng, Weiping
    Stone, Ivan
    Klussman, Kerry
    Ulrich, Michelle
    Jonas, Mechthild
    Senter, Peter
    Drachman, Jonathan G.
    Benjamin, Dennis
    BLOOD, 2015, 126 (23)
  • [5] SGN-CD228A Is an Investigational CD228-Directed Antibody-Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
    Mazahreh, Rebecca
    Mason, Marsha L.
    Gosink, John J.
    Olson, Devra J.
    Thurman, Robert
    Hale, Christopher
    Westendorf, Lori
    Pires, Thomas A.
    Leiske, Christopher I.
    Carlson, Markus
    Nguyen, Liem T.
    Cochran, Julia H.
    Okeley, Nicole M.
    Yumul, Roma
    Jin, Steven
    Stone, Ivan J.
    Sahetya, Disha
    Nesterova, Albina
    Allred, Sean
    Hensley, Kelly M.
    Hu, Rachael
    Lawrence, Robert
    Lewis, Timothy S.
    Sandall, Sharsti
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (04) : 421 - 434
  • [6] IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML
    Kovtun, Yelena
    Noordhuis, Paul
    Whiteman, Kathleen R.
    Watkins, Krystal
    Jones, Gregory E.
    Harvey, Lauren
    Lai, Katharine C.
    Portwood, Scott
    Adams, Sharlene
    Sloss, Callum M.
    Schuurhuis, Gerrit Jan
    Ossenkoppele, Gert
    Wang, Eunice S.
    Pinkas, Jan
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (06) : 1271 - 1279
  • [7] Anti-CD70 antibody-drug conjugates containing pyrrolobenzodiazepine dimers demonstrate robust antitumor activity
    Jeffrey, Scott
    Burke, Patrick
    Meyer, David
    Lyon, Robert
    Miyamoto, Jamie
    Anderson, Martha
    Stone, Ivan
    Law, Che-Leung
    Senter, Peter
    CANCER RESEARCH, 2012, 72
  • [8] SGN-35C: A Novel CD30-Directed Antibody-Drug Conjugate for the Treatment of Lymphomas
    Hamblett, Kevin J.
    Cochran, Julia
    Snead, Katie
    Jin, Steven
    Yumul, Roma
    Simmons, Jessica
    Stone, Ivan
    Lyski, Ryan
    Schrum, Jason P.
    Lim, Andrea R.
    Clarke, Astrid
    BLOOD, 2023, 142
  • [9] Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts
    Jones, Luke
    McCalmont, Hannah
    Evans, Kathryn
    Mayoh, Chelsea
    Kurmasheva, Raushan T.
    Billups, Catherine A.
    Houghton, Peter J.
    Smith, Malcolm A.
    Lock, Richard B.
    PEDIATRIC BLOOD & CANCER, 2019, 66 (08)
  • [10] SGN-CD19B, a Pyrrolobenzodiazepine (PBD)-Based Anti-CD19 Drug Conjugate, Demonstrates Potent Preclinical Activity Against B-Cell Malignancies
    Ryan, Maureen C.
    Schimpf, Brian
    Anderson, Martha
    Zeng, Weiping
    Emmerton, Kim
    Miyamoto, Jamie
    Kostner, Heather
    Yu, Changpu
    Van Epps, Heather
    Tatalick, Laurie
    Benjamin, Dennis
    BLOOD, 2015, 126 (23)
12345